BlackRock Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | $8.91M | Sell |
237,918
-274,177
| -54% | -$10.3M | ﹤0.01% | 945 |
|
|
2016
Q3 | $34.7M | Sell |
512,095
-45,363
| -8% | -$3.07M | 0.02% | 667 |
|
|
2016
Q2 | $30.9M | Buy |
557,458
+37,624
| +7% | +$2.09M | 0.02% | 678 |
|
|
2016
Q1 | $32.6M | Buy |
519,834
+93,450
| +22% | +$5.87M | 0.02% | 678 |
|
|
2015
Q4 | $40.1M | Buy |
426,384
+10,479
| +3% | +$986K | 0.02% | 631 |
|
|
2015
Q3 | $33.4M | Buy |
415,905
+146,528
| +54% | +$11.8M | 0.02% | 663 |
|
|
2015
Q2 | $32.3M | Buy |
269,377
+189,632
| +238% | +$22.7M | 0.02% | 696 |
|
|
2015
Q1 | $8.33M | Buy |
79,745
+42,120
| +112% | +$4.4M | ﹤0.01% | 1002 |
|
|
2014
Q4 | $3.65M | Buy |
37,625
+8,060
| +27% | +$782K | ﹤0.01% | 1218 |
|
|
2014
Q3 | $2.31M | Sell |
29,565
-33,001
| -53% | -$2.58M | ﹤0.01% | 1350 |
|
|
2014
Q2 | $3.95M | Buy |
62,566
+19,196
| +44% | +$1.21M | ﹤0.01% | 1188 |
|
|
2014
Q1 | $2.91M | Buy |
43,370
+10,351
| +31% | +$695K | ﹤0.01% | 1330 |
|
|
2013
Q4 | $2.12M | Sell |
33,019
-321,767
| -91% | -$20.7M | ﹤0.01% | 1473 |
|
|
2013
Q3 | $22.7M | Buy |
354,786
+15,678
| +5% | +$1M | 0.02% | 729 |
|
|
2013
Q2 | $10.5M | Buy |
+339,108
| New | +$10.5M | 0.01% | 844 |
|